AXIN1 and hepatocellular carcinoma: Studies have shown that CTNNB mutation status was related to the upregulation of Wnt/β-catenin pathway genes instead of AXIN1 mutation and AXIN1 mutation was unlikely to be a strong driving factor in the development of HCC in humans (62), which may explain why the low-risk group had a better prognosis despite the higher frequency of AXIN1 mutations.